FDA Accepts Pfizer’s sNDA for BRAFTOVI + MEKTOVI
LifeProNow
APRIL 9, 2023
Detailed results from the PHAROS study will be presented at an upcoming scientific congress. In 2018, the FDA approved BRAFTOVI + MEKTOVI in combination for patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation, as detected by an FDA-approved test. of patients.
Let's personalize your content